{"id":542952,"date":"2021-05-12T19:14:01","date_gmt":"2021-05-12T19:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542952"},"modified":"2021-05-12T19:14:01","modified_gmt":"2021-05-12T19:14:01","slug":"oropharyngeal-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-astrazeneca-isa-pharmaceuticals-pfizer-bristol-myers-squibb-advaxis-pds-biotechnology-sanofi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oropharyngeal-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-astrazeneca-isa-pharmaceuticals-pfizer-bristol-myers-squibb-advaxis-pds-biotechnology-sanofi_542952.html","title":{"rendered":"Oropharyngeal Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Sanofi"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620803012.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Oropharyngeal Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Sanofi\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620803012.jpeg\" alt=\"Oropharyngeal Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Sanofi\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Oropharyngeal Cancer Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Oropharyngeal cancer&nbsp;<\/strong>is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs. And although rare, lymphoma, or cancer affecting cells in the lymphatic system, can also occur at the base of the tongue and tonsils, which are made up of lymph tissue.<\/p>\n<p style=\"text-align: justify;\">&#8220;DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oropharyngeal-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Oropharyngeal cancer Pipeline<\/a><\/strong> Insight, 2021,&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oropharyngeal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Oropharyngeal cancer Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AstraZeneca<\/li>\n<li>ISA Pharmaceuticals<\/li>\n<li>Pfizer<\/li>\n<li>Bristol Myers Squibb<\/li>\n<li>Advaxis<\/li>\n<li>PDS Biotechnology<\/li>\n<li>Debiopharm<\/li>\n<li>Merck KGaA<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Sanofi<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Oropharyngeal cancer report covers around 10+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oropharyngeal-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Oropharyngeal cancer Therapies<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cisplatin<\/li>\n<li>ISA101B<\/li>\n<li>Utomilumab<\/li>\n<li>Nivolumab<\/li>\n<li>ADXS11-001<\/li>\n<li>Durvalumab<\/li>\n<li>PDS0101<\/li>\n<li>Tipapkinogene sovacivec<\/li>\n<li>Avelumab<\/li>\n<li>Cemiplimab<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Oropharyngeal cancer Treatment Scenario and Oropharyngeal cancer Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Oropharyngeal cancer drugs?<\/li>\n<li>How many Oropharyngeal cancer drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oropharyngeal cancer?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Oropharyngeal cancer therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Oropharyngeal cancer and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Cisplatin: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">ISA101B: ISA Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early stage products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Genakumab: GeneScience Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer Key Companies<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer Key Products<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer Analyst Views<\/p>\n<p style=\"text-align: justify;\">Oropharyngeal cancer Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/oropharyngeal-cancer-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=oropharyngeal-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-astrazeneca-isa-pharmaceuticals-pfizer-bristol-myers-squibb-advaxis-pds-biotechnology-sanofi\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/oropharyngeal-cancer-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/oropharyngeal-cancer-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/oropharyngeal-cancer-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=oropharyngeal-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-astrazeneca-isa-pharmaceuticals-pfizer-bristol-myers-squibb-advaxis-pds-biotechnology-sanofi\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oropharyngeal Cancer Pipeline Oropharyngeal cancer&nbsp;is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/oropharyngeal-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-astrazeneca-isa-pharmaceuticals-pfizer-bristol-myers-squibb-advaxis-pds-biotechnology-sanofi_542952.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-542952","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542952"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}